Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy

Phase 4

Completed

Conditions: BPH/LUTS/Sexual Functions

First Posted Date: 2007-10-10

Last Posted Date: 2007-10-11

Lead Sponsor: Sanofi

Target Recruit Count: 166

Registration Number: NCT00542165

Locations: 🇰🇷
Sanofi-Aventis, Seoul, Korea, Republic of

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: gemcitabine/carboplatin
Drug: iniparib

First Posted Date: 2007-10-08

Last Posted Date: 2012-12-28

Lead Sponsor: Sanofi

Target Recruit Count: 123

Registration Number: NCT00540358

Locations: 🇺🇸
Research Site, Yakima, Washington, United States

PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro

Phase 4

Completed

Conditions: Diabetes Mellitus

First Posted Date: 2007-10-08

Last Posted Date: 2012-02-17

Lead Sponsor: Sanofi

Target Recruit Count: 58

Registration Number: NCT00540709

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

Phase 3

Completed

Conditions: Benign Prostatic Hyperplasia

First Posted Date: 2007-10-08

Last Posted Date: 2007-10-08

Lead Sponsor: Sanofi

Target Recruit Count: 372

Registration Number: NCT00540891

Locations: 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States

Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
Drug: Coartem® (arthemether+ lumefantrine)

First Posted Date: 2007-10-08

Last Posted Date: 2010-06-23

Lead Sponsor: Sanofi

Target Recruit Count: 366

Registration Number: NCT00540410

Locations: 🇸🇳
Sanofi-Aventis Administrative Office, Dakar, Senegal

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: FluBlok®
Biological: Placebo

First Posted Date: 2007-10-05

Last Posted Date: 2022-04-06

Lead Sponsor: Sanofi

Target Recruit Count: 4648

Registration Number: NCT00539981

Locations: 🇺🇸
Benchmark Research - Sacramento, Sacramento, California, United States
🇺🇸
Impact Clinical Trials, Beverly Hills, California, United States
🇺🇸
University Clinical Research, Inc, Pembroke Pines, Florida, United States

and more 21 locations